Alwin Capital — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

Neukioneukio.comSep 2022 · $50M

Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases.

BiotechDeep TechHealthtech

Liqun Wang(Founder)

Co-investorsPan-Lin Capital IDG Capital Lilly Asia Ventures Sherpa Healthcare Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.